Tramadol

Identification

Name
Tramadol
Accession Number
DB00193  (APRD00028)
Type
Small Molecule
Groups
Approved, Investigational
Description

A narcotic analgesic proposed for moderate to severe pain. It may be habituating. Tramadol is also prepared as a variable release capsules, marketed under the brand name ConZip. For example, a 150 mg capsule will contain 37.5 mg of the immediate release form and 112.5 mg of the extended release form.

Structure
Thumb
Synonyms
  • (+)-Tramadol
  • (+)-trans-2-(Dimethylaminomethyl)-1-(m-methoxyphenyl)cyclohexanol
External IDs
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Tramadol hydrochloride9N7R477WCK 36282-47-0PPKXEPBICJTCRU-XMZRARIVSA-N
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ConZipCapsule, extended release300 mg/1OralVertical Pharmaceuticals, Inc.2011-08-31Not applicableUs
ConZipCapsule, extended release200 mg/1OralVertical Pharmaceuticals, Inc.2011-08-312017-04-14Us
ConZipCapsule, extended release100 mg/1OralVertical Pharmaceuticals, Inc.2011-08-31Not applicableUs
ConZipCapsule, extended release300 mg/1OralVertical Pharmaceuticals, Inc.2011-08-312017-04-14Us
ConZipCapsule, extended release200 mg/1OralVertical Pharmaceuticals, Inc.2011-08-31Not applicableUs
ConZipCapsule, extended release100 mg/1OralVertical Pharmaceuticals, Inc.2011-08-312017-04-14Us
DurelaCapsule, extended release100 mgOralCipher Pharmaceuticals Inc.2012-03-19Not applicableCanada
DurelaCapsule, extended release200 mgOralCipher Pharmaceuticals Inc.2012-03-19Not applicableCanada
DurelaCapsule, extended release300 mgOralCipher Pharmaceuticals Inc.2012-03-19Not applicableCanada
RaliviaTablet, extended release300 mgOralValeant Canada Lp Valeant Canada S.E.C.2007-10-25Not applicableCanada
RaliviaTablet, extended release100 mgOralValeant Canada Lp Valeant Canada S.E.C.2007-10-25Not applicableCanada
RaliviaTablet, extended release200 mgOralValeant Canada Lp Valeant Canada S.E.C.2007-10-25Not applicableCanada
RyzoltTablet, extended release300 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-03-222016-12-15Us
RyzoltTablet, extended release200 mg/1OralStat Rx USA2008-12-30Not applicableUs
RyzoltTablet, extended release100 mg/1OralStat Rx USA2008-12-30Not applicableUs
RyzoltTablet, extended release300 mg/1OralStat Rx USA2008-12-30Not applicableUs
Taro-tramadol ERTablet, extended release300 mgOralTaro Pharmaceuticals, Inc.2016-05-27Not applicableCanada
Taro-tramadol ERTablet, extended release100 mgOralTaro Pharmaceuticals, Inc.2016-03-07Not applicableCanada
Taro-tramadol ERTablet, extended release200 mgOralTaro Pharmaceuticals, Inc.2016-05-27Not applicableCanada
Tramadol HydrochlorideTablet, extended release100 mg/1OralRemedy Repack2013-05-082017-03-16Us
Tramadol HydrochlorideCapsule150 mg/1OralDirectrx2015-01-01Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralAidarex Pharmaceuticals LLC2015-07-01Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralH.J. Harkins Company2012-03-14Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralPatriot Pharmaceuticals2006-01-16Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralNucare Pharmaceuticals, Inc.2015-07-01Not applicableUs
Tramadol HydrochlorideCapsule, coated, extended release150 mg/1OralDirectrx2014-01-01Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralUnit Dose Services2015-07-01Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralSa3, Llc2017-04-012017-04-15Us
Tramadol HydrochlorideCapsule, extended release150 mg/1OralPreferreed Pharmaceuticals Inc.2012-07-172016-10-13Us
Tramadol HydrochlorideCapsule, extended release150 mg/1OralA S Medication Solutions2012-03-142017-06-20Us
Tramadol HydrochlorideCapsule, extended release150 mg/1OralProficient Rx LP2012-03-14Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralAidarex Pharmaceuticals LLC2015-07-01Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralKLE 2, Inc.2012-03-142015-12-29Us
Tramadol HydrochlorideTablet, extended release200 mg/1OralPatriot Pharmaceuticals2006-01-16Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralAidarex Pharmaceuticals LLC2012-03-14Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2012-03-142016-12-24Us
Tramadol HydrochlorideCapsule, extended release150 mg/1OralSa3, Llc2017-04-01Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralUnit Dose Services2012-03-142017-07-03Us
Tramadol HydrochlorideCapsule, extended release150 mg/1OralSta3, Llc2015-07-01Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1Oralbryant ranch prepack2012-03-14Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralProficient Rx LP2015-07-01Not applicableUs
Tramadol HydrochlorideTablet, extended release300 mg/1OralPatriot Pharmaceuticals2006-01-16Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralMesource Pharmaceuticals2012-03-14Not applicableUs
Tramadol HydrochlorideCapsule, extended release150 mg/1OralA S Medication Solutions2012-03-142017-06-20Us
Tramadol HydrochlorideCapsule, extended release150 mg/1OralPreferreed Pharmaceuticals Inc.2015-09-18Not applicableUs
Tramadol Hydrochloride Extended-ReleaseCapsule100 mg/1OralTrigen Laboratories, Inc.2015-06-22Not applicableUs
Tramadol Hydrochloride Extended-ReleaseCapsule200 mg/1OralTrigen Laboratories, Inc.2015-06-22Not applicableUs
Tramadol Hydrochloride Extended-ReleaseCapsule300 mg/1OralTrigen Laboratories, Inc.2015-06-22Not applicableUs
TriduralTablet, extended release100 mgOralPaladin Labs Inc2007-08-14Not applicableCanada
TriduralTablet, extended release200 mgOralPaladin Labs Inc2007-08-14Not applicableCanada
TriduralTablet, extended release300 mgOralPaladin Labs Inc2007-08-14Not applicableCanada
UltramTablet, coated50 mg/1OralJanssen Pharmaceuticals1995-03-03Not applicableUs
UltramTablet, coated50 mg/1OralA S Medication Solutions1995-03-032017-06-20Us
UltramTablet50 mgOralJanssen Pharmaceuticals2010-06-28Not applicableCanada
UltramTablet, coated50 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2012-03-20Not applicableUs
UltramTablet, coated50 mg/1OralPd Rx Pharmaceuticals, Inc.1995-03-03Not applicableUs
UltramTablet, coated50 mg/1OralA S Medication Solutions1995-03-032017-06-20Us
Ultram ERTablet, extended release300 mg/1OralRebel Distributors2005-09-08Not applicableUs
Ultram ERTablet, extended release300 mg/1OralJanssen Pharmaceuticals2005-10-01Not applicableUs
Ultram ERTablet, extended release300 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2011-12-272017-09-16Us
Ultram ERTablet100 mg/1OralRemedy Repack2012-03-012016-10-28Us
Ultram ERTablet, extended release100 mg/1OralRebel Distributors2005-09-08Not applicableUs
Ultram ERTablet, extended release100 mg/1OralJanssen Pharmaceuticals2005-10-01Not applicableUs
Ultram ERTablet, extended release200 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-03-20Not applicableUs
Ultram ERTablet, extended release200 mg/1OralRebel Distributors2005-09-08Not applicableUs
Ultram ERTablet, extended release200 mg/1OralJanssen Pharmaceuticals2005-10-01Not applicableUs
Ultram ERTablet, extended release100 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2011-12-272017-09-16Us
Zytram XLTablet, extended release200 mgOralPurdue Pharma2006-12-07Not applicableCanada
Zytram XLTablet, extended release150 mgOralPurdue Pharma2006-12-07Not applicableCanada
Zytram XLTablet, extended release100 mgOralPurdue Pharma2011-03-02Not applicableCanada
Zytram XLTablet, extended release300 mgOralPurdue Pharma2006-12-07Not applicableCanada
Zytram XLTablet, extended release75 mgOralPurdue Pharma2011-03-02Not applicableCanada
Zytram XLTablet, extended release400 mgOralPurdue Pharma2006-12-07Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-tramadolTablet50 mgOralApotex Corporation2014-06-23Not applicableCanada
TramadolTablet50 mg/1OralAccord Healthcare Limited2013-10-012017-01-27Us
Tramadol ERTablet, extended release200 mg/1OralStat Rx USA2009-10-27Not applicableUs49884 0822 11 nlmimage10 b9125cd2
Tramadol HydrchlorideTablet50 mg/1OralRemedy Repack2011-09-282016-11-15Us65162 0627 11 nlmimage10 5212a925
Tramadol HydrochlorideTablet50 mg/1OralKeltman Pharmaceuticals Inc.2009-06-30Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralMajor2014-02-26Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralUnit Dose Services2010-11-15Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralRed Pharm Drug, Inc.2015-05-22Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralStat Rx USA2009-11-23Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1Oralbryant ranch prepack2010-11-15Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralNorth Star Rx Llc2011-02-16Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralAurobindo Pharma2014-03-31Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralA S Medication Solutions2002-06-222017-06-20Us
Tramadol HydrochlorideTablet50 mg/1OralApotheca, Inc.2005-04-26Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralUnit Dose Services2002-06-22Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralSt. Marys Medical Park Pharmacy2014-10-06Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralRemedy Repack2010-11-172016-10-13Us
Tramadol HydrochlorideTablet, extended release100 mg/1OralMylan Pharmaceuticals2016-03-16Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralDirectrx2016-12-01Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralCardinal Health2002-06-22Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2015-05-22Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralDispensing Solutions, Inc.2002-06-22Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralRemedy Repack2013-05-072016-10-13Us00093 0058 01 nlmimage10 00280060
Tramadol HydrochlorideTablet, extended release300 mg/1OralSun Pharma Global FZE2011-12-12Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralTeva2002-06-20Not applicableUs
Tramadol HydrochlorideTablet, extended release300 mg/1OralGolden State Medical Supply2016-10-20Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralRebel Distributors2009-11-13Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralMylan Institutional2002-08-01Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-06-21Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralContract Pharmacy Services Pa2011-01-31Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralApotex Corporation2002-07-102017-03-07Us
Tramadol HydrochlorideTablet, extended release100 mg/1OralDispensing Solutions, Inc.2009-11-13Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralA S Medication Solutions2002-06-222017-06-20Us
Tramadol HydrochlorideTablet, extended release200 mg/1OralRemedy Repack2016-09-15Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralSun Pharma Global FZE2011-12-12Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralVirtus Pharmaceuticals2015-05-22Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralMacleods Pharmaceuticals Limited2015-10-07Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralPar Pharmaceutical2009-11-13Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralPd Rx Pharmaceuticals, Inc.2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralMc Kesson Contract Packaging2011-10-19Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralAmerincan Health Packaging2014-08-21Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralGolden State Medical Supply2016-10-20Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1Oralbryant ranch prepack2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralMesource Pharmaceuticals2014-02-14Not applicableUs76439 0136 11 nlmimage10 3247994c
Tramadol HydrochlorideTablet, film coated50 mg/1OralNu Care Pharmaceuticals,inc.2011-01-31Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralRebel Distributors2009-11-13Not applicableUs49884 0821 11 nlmimage10 bd125e82
Tramadol hydrochlorideTablet, extended release300 mg/1OralAurobindo Pharma2015-10-20Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralPhysicians Total Care, Inc.2002-06-21Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralNorth Star Rx Llc2016-04-06Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralA S Medication Solutions2010-11-152017-06-20Us
Tramadol HydrochlorideTablet, extended release100 mg/1OralProficient Rx LP2011-12-12Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralA S Medication Solutions2002-06-222017-06-20Us
Tramadol HydrochlorideTablet, coated50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralSun Pharma Global FZE2011-12-30Not applicableUs
Tramadol HydrochlorideTablet, extended release300 mg/1OralLupin Pharmaceuticals2011-09-262015-12-31Us
Tramadol HydrochlorideTablet, extended release200 mg/1OralPreferreed Pharmaceuticals Inc.2014-10-062016-12-07Us
Tramadol HydrochlorideTablet, coated50 mg/1OralCardinal Health2010-11-15Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralUnit Dose Services2015-05-22Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralReady Meds2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralNucare Pharmaceuticals, Inc.2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, extended release300 mg/1OralUnit Dose Services2011-09-21Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralLupin Pharmaceuticals2014-08-18Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2011-06-01Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralUnit Dose Services2011-12-30Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralStat Rx USA2002-06-22Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralZydus Pharmaceuticals Usa, Inc.2011-01-31Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralRed Pharm Drug, Inc.2015-10-07Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralMajor2010-03-01Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralGolden State Medical Supply2017-08-24Not applicableUs
Tramadol HydrochlorideTablet50 mg/50mgOralAlivio Medical Products, Llc2015-10-01Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralRemedy Repack2011-12-05Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2011-12-12Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralNucare Pharmaceuticals, Inc.2011-01-31Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralPd Rx Pharmaceuticals, Inc.2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralCardinal Health2011-02-04Not applicableUs
Tramadol hydrochlorideTablet, extended release100 mg/1OralAurobindo Pharma2015-10-20Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralA S Medication Solutions2009-11-132017-06-20Us
Tramadol HydrochlorideTablet, film coated50 mg/1OralCitron Pharma LLC2014-03-31Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralPreferreed Pharmaceuticals Inc.2016-08-22Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralDirectrx2014-01-01Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralMylan Pharmaceuticals2016-03-16Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralPreferreed Pharmaceuticals Inc.2015-09-22Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralCardinal Health2010-03-23Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralDirectrx2014-01-01Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralContract Pharmacy Services Pa2010-02-26Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralRemedy Repack2013-05-132016-10-13Us
Tramadol HydrochlorideTablet50 mg/1OralA S Medication Solutions2002-06-222017-06-20Us
Tramadol HydrochlorideTablet50 mg/1OralSun Pharmaceutical Industries Limited2002-06-22Not applicableUs57664 0377 18 nlmimage10 4d12a685
Tramadol HydrochlorideTablet, coated50 mg/1OralAmneal Pharmaceuticals2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralAidarex Pharmaceuticals LLC2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralA S Medication Solutions2010-11-152017-06-20Us
Tramadol HydrochlorideTablet, coated50 mg/1OralMc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation2013-12-02Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralA S Medication Solutions2009-11-132017-06-20Us
Tramadol HydrochlorideTablet, extended release200 mg/1OralSun Pharma Global FZE2011-12-30Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralRemedy Repack2017-02-23Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralRed Pharm Drug, Inc.2002-06-22Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralRxchange Co2014-11-14Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralPar Pharmaceutical2009-11-13Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralBlenheim Pharmacal, Inc.2010-08-13Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralRemedy Repack2015-11-23Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralVirtus Pharmaceuticals2014-02-20Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralPreferreed Pharmaceuticals Inc.2009-11-23Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralPhysicians Total Care, Inc.2010-11-17Not applicableUs
Tramadol HydrochlorideTablet, extended release300 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2011-12-12Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralUnit Dose Services2011-12-30Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralContract Pharmacy Services Pa2002-06-22Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralPreferreed Pharmaceuticals Inc.2015-04-15Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralCardinal Health2010-03-01Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralRed Pharm Drug, Inc.2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralCadila Pharnmaceuticals2011-01-31Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralRemedy Repack2013-06-042016-10-13Us
Tramadol HydrochlorideTablet, extended release100 mg/1OralAmerincan Health Packaging2015-03-312018-02-28Us
Tramadol HydrochlorideTablet, coated50 mg/1OralAidarex Pharmaceuticals LLC2010-11-152017-03-09Us
Tramadol HydrochlorideTablet, extended release300 mg/1OralLupin Pharmaceuticals2014-08-18Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralCardinal Health2002-06-21Not applicableUs00378 4151 01 nlmimage10 2a21954c
Tramadol HydrochlorideTablet50 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2009-11-23Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralLupin Pharmaceuticals2011-09-262016-05-31Us
Tramadol HydrochlorideTablet, extended release100 mg/1OralRemedy Repack2014-01-092016-10-13Us
Tramadol HydrochlorideTablet, coated50 mg/1OralNucare Pharmaceuticals, Inc.2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralSun Pharma Global FZE2011-12-12Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralPreferreed Pharmaceuticals Inc.2017-03-22Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralAidarex Pharmaceuticals LLC2002-06-22Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralNucare Pharmaceuticals, Inc.2011-01-31Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralRemedy Repack2017-01-12Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralLife Line Home Care Services2011-01-01Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralRemedy Repack2015-02-262017-03-15Us
Tramadol HydrochlorideTablet, extended release100 mg/1OralGolden State Medical Supply2016-10-20Not applicableUs
Tramadol HydrochlorideTablet50 mg/1Oralbryant ranch prepack2002-06-22Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralAphena Pharma Solutions Tennessee, Inc.2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralRemedy Repack2015-04-01Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralRebel Distributors2009-11-23Not applicableUs
Tramadol hydrochlorideTablet, extended release200 mg/1OralAurobindo Pharma2015-10-20Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralPhysicians Total Care, Inc.2010-03-08Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralBiomes Pharmaceuticals2016-02-25Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralDirectrx2014-01-01Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2011-02-072017-03-17Us
Tramadol HydrochlorideTablet, extended release300 mg/1OralMylan Pharmaceuticals2016-03-16Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralRemedy Repack2016-12-12Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralCardinal Health2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralA S Medication Solutions2011-12-122017-06-20Us
Tramadol HydrochlorideTablet50 mg/1OralAltura Pharmaceuticals, Inc.2010-01-01Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralMed Pharma Co., Ltd.2011-01-01Not applicableUs
Tramadol HydrochlorideTablet, extended release300 mg/1OralSun Pharma Global FZE2011-12-30Not applicableUs
Tramadol HydrochlorideTablet, film coated50 mg/1OralMylan Pharmaceuticals2002-06-21Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralLupin Pharmaceuticals2014-08-18Not applicableUs
Tramadol HydrochlorideTablet, extended release100 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2011-06-01Not applicableUs
Tramadol HydrochlorideTablet, extended release300 mg/1OralPar Pharmaceutical2011-09-21Not applicableUs
Tramadol HydrochlorideTablet50 mg/1OralBlenheim Pharmacal, Inc.2010-04-07Not applicableUs
Tramadol HydrochlorideTablet, coated50 mg/1OralProficient Rx LP2010-11-15Not applicableUs
Tramadol HydrochlorideTablet, extended release200 mg/1OralLupin Pharmaceuticals2011-09-262015-11-30Us
Tramadol HydrochlorideTablet, extended release300 mg/1OralPreferreed Pharmaceuticals Inc.2014-10-06Not applicableUs
Tramadol Hydrochloride ERTablet, extended release100 mg/1OralDirectrx2014-01-01Not applicableUs
Tramadol Hydrochloride Extended-ReleaseTablet, film coated, extended release100 mg/1OralPar Pharmaceutical2012-06-27Not applicableUs
Tramadol Hydrochloride Extended-ReleaseTablet, film coated, extended release300 mg/1OralPar Pharmaceutical2012-06-27Not applicableUs
Tramadol Hydrochloride Extended-ReleaseTablet, film coated, extended release200 mg/1OralPar Pharmaceutical2012-06-27Not applicableUs
UltramTablet, coated50 mg/201OralNorthwind Pharmaceuticals2014-02-13Not applicableUs
Approved Over the Counter Products
Not Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SynaprynKitOralFusion Pharmaceuticals LLC2009-09-14Not applicableUs
SynaprynKitCalifornia Pharmaceuticals, Llc2017-05-01Not applicableUs
International/Other Brands
Rybix / Tramal (Grünenthal GmbH)
Brand mixtures
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Act Tramadol/acetTabletOralActavis Pharma Company2012-05-01Not applicableCanada
Apo-tramadol/acetTabletOralApotex Corporation2009-11-09Not applicableCanada
Auro-tramadol/acetaminophenTabletOralAuro Pharma Inc2015-04-08Not applicableCanada
Ipg-tramadol/acetTabletOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-acet-tramadolTabletOralJamp Pharma Corporation2012-09-05Not applicableCanada
Lupin-tramadol/acetTabletOralLupin PharmaNot applicableNot applicableCanada
Mar-tramadol/acetTabletOralMarcan Pharmaceuticals Inc2012-09-04Not applicableCanada
Mint-tramadol/acetTabletOralMint Pharmaceuticals Inc2012-09-18Not applicableCanada
Mylan-tramadol/acetTabletOralMylan Pharmaceuticals2015-01-302017-05-08Canada
Pat-tramadol/acetTabletOralPatriot A Division Of Janssen Inc2012-08-142014-11-11Canada
PMS-tramadol-acetTabletOralPharmascience Inc2013-04-29Not applicableCanada
Priva-tramadol/acetTabletOralPharmapar Inc2013-07-09Not applicableCanada
Ran-tramadol/acetTabletOralRanbaxy Inc.2012-10-01Not applicableCanada
Riva-tramadol/acetTabletOralLaboratoire Riva Inc2014-12-122015-07-22Canada
Teva-tramadol/acetaminophenTabletOralTeva2012-09-04Not applicableCanada
Theratramadol-90KitPhysician Therapeutics Llc2011-02-042016-10-13Us
Topical PainCreamTopicalDr Marc's Manufacturing And Sales2016-02-23Not applicableUs
TramacetTabletOralJanssen Pharmaceuticals2005-07-22Not applicableCanada
Tramadal Hydrochloride and AcetaminophenTabletOralRemedy Repack2011-10-172017-04-14Us
Tramadol / AcetaminophenTabletOralSivem Pharmaceuticals Ulc2015-01-13Not applicableCanada
Tramadol AcetaminophenTabletOralDirectrx2015-01-01Not applicableUs
Tramadol HCl and AcetaminophenTablet, film coatedOralAscend Laboratories, LLC2016-06-15Not applicableUs
Tramadol Hydrochloride and AcetaminophenTablet, coatedOralStat Rx USA2001-08-15Not applicableUs00172 6359 60 nlmimage10 cb2d658b
Tramadol-acetTabletOralPro Doc Limitee2014-02-03Not applicableCanada
Tramadol/acetTabletOralSanis Health Inc2014-07-25Not applicableCanada
TramapapKitLiving Well Pharmacy, Inc.2010-04-07Not applicableUs
Tramaphen-odanTabletOralOdan Laboratories Ltd2012-09-052014-10-31Canada
UltracetTabletOralRebel Distributors2001-08-15Not applicableUs00045 0650 60 nlmimage10 ec127653
Categories
UNII
39J1LGJ30J
CAS number
27203-92-5
Weight
Average: 263.3752
Monoisotopic: 263.188529049
Chemical Formula
C16H25NO2
InChI Key
TVYLLZQTGLZFBW-ZBFHGGJFSA-N
InChI
InChI=1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1
IUPAC Name
(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol
SMILES
COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C

Pharmacology

Indication

Indicated in the treatment of moderate to severe pain. Consider for those prone to constipation or respiratory depression. Tramadol is used to treat postoperative, dental, cancer, and acute musculosketetal pain and as an adjuvant to NSAID therapy in patients with osteoarthritis.

Structured Indications
Pharmacodynamics

Tramadol, a centrally-acting analgesic, exists as a racemic mixture of the trans isomer, with important differences in binding, activity, and metabolism associated with the two enantiomers. Although its mode of action is not completely understood, from animal tests, at least two complementary mechanisms appear applicable: binding of parent and M1 metabolite to μ-opioid receptors and weak inhibition of reuptake of norepinephrine and serotonin. Opioid activity is due to both low affinity binding of the parent compound and higher affinity binding of the O-demethylated metabolite M1 to μ-opioid receptors. In animal models, M1 is up to 6 times more potent than tramadol in producing analgesia and 200 times more potent in μ-opioid binding. Opiate antagonist naloxone only partially antagonized tramadol-induced analgesia.

Mechanism of action

Tramadol and its O-desmethyl metabolite (M1) are selective, weak OP3-receptor agonists. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. The analgesic properties of Tramadol can be attributed to norepinephrine and serotonin reuptake blockade in the CNS, which inhibits pain transmission in the spinal cord. The (+) enantiomer has higher affinity for the OP3 receptor and preferentially inhibits serotonin uptake and enhances serotonin release. The (-) enantiomer preferentially inhibits norepinephrine reuptake by stimulating alpha(2)-adrenergic receptors.

TargetActionsOrganism
AMu-type opioid receptor
agonist
Human
ASodium-dependent noradrenaline transporter
inhibitor
Human
ASodium-dependent serotonin transporter
inhibitor
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
UKappa-type opioid receptor
agonist
Human
NDelta-type opioid receptor
agonist
Human
UGlutamate receptor ionotropic, NMDA 3A
antagonist
Human
UAlpha-7 nicotinic cholinergic receptor subunit
antagonist
Human
UMuscarinic acetylcholine receptor M3
antagonist
Human
Absorption

Racemic tramadol is rapidly and almost completely absorbed after oral administration. The mean absolute bioavailability of a 100 mg oral dose is approximately 75%. The mean peak plasma concentration of racemic tramadol and M1 occurs at two and three hours, respectively, after administration in healthy adults.

Volume of distribution
  • 2.6 L/kg [male, 100 mg intravenous dose]
  • 2.9 L/kg [female, 100 mg intravenous dose]
Protein binding

20% bound to plasma proteins.

Metabolism

Hepatic. The major metabolic pathways appear to be N- and O- demethylation and glucuronidation or sulfation in the liver. One metabolite (O-desmethyltramadol, denoted M1) is pharmacologically active in animal models. CYP3A4 and CYP2B6 facilitates the biotransformation of tramadol to N-desmethyl-tramadol. CYP2D6 facilitates the biotransformation of tramadol to O-desmethyl-tramadol.

Route of elimination

Tramadol is eliminated primarily through metabolism by the liver and the metabolites are excreted primarily by the kidneys. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% of the dose is excreted as metabolites.

Half life

Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.

Clearance
  • 5.9 mL/min/Kg [Healthy Adults, 100 mg qid, MD p.o]
  • 8.5 mL/min/Kg [Healthy Adults, 100 mg SD p.o]
  • 6.89 mL/min/Kg [Geriatric, (<75 yr), 50 mg SD p.o.]
  • 4.23 mL/min/Kg [Hepatic Impaired, 50 mg SD p.o.]
  • 4.23 mL/min/Kg [Renal Impaired, Clcr10-3mL/min, 100 mg SD i.v.]
  • 3.73 mL/min/Kg [Renal Impaired, CLcr<5 mL/min, 100 mg SD i.v.]
  • 6.4 mL/min/Kg [Male following a 100 mg IV dose]
  • 5.7 mL/min/Kg [Female following a 100 mg IV dose]
Toxicity

LD50=350mg/kg (orally in mice)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Tramadol Metabolism PathwayDrug metabolism
Tramadol Action Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableC allele ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableC allele ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delT ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>C ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>T ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>C ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>A ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>A ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACT ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insG ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACT ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2 ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGT ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>T ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all ADR Inferred EffectPoor drug metabolizer. This results in reduced analgesic efficacy and decreased risk of opioid toxicity as well as increased risk of seizures and serotonin syndrome. Consider alternative therapies.Details

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Tramadol.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Tramadol.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Tramadol.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Tramadol.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Tramadol is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineTramadol may increase the neuroexcitatory activities of 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AbirateroneThe serum concentration of Tramadol can be increased when it is combined with Abiraterone.Approved
AcenocoumarolTramadol may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Tramadol is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Acetophenazine.Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Tramadol.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Tramadol is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Tramadol is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Tramadol is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Tramadol is combined with Alfentanil.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Tramadol.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Tramadol is combined with Sage 547.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Almotriptan.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Alprazolam.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Tramadol is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Tramadol is combined with Amiloride.Approved
AmineptineAmineptine may increase the neuroexcitatory activities of Tramadol.Illicit, Withdrawn
AmiodaroneThe therapeutic efficacy of Tramadol can be decreased when used in combination with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Tramadol is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may increase the neuroexcitatory activities of Tramadol.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Tramadol which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Tramadol is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Tramadol is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Tramadol.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Tramadol.Approved
AprepitantThe serum concentration of Tramadol can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Tramadol is combined with Aripiprazole.Approved, Investigational
ArtemetherThe therapeutic efficacy of Tramadol can be decreased when used in combination with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Tramadol is combined with Asenapine.Approved
AtazanavirThe serum concentration of Tramadol can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Atomoxetine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tramadol.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Tramadol.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Azaperone.Vet Approved
AzelastineTramadol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Tramadol is combined with Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Tramadol is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Tramadol is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Tramadol.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Bendroflumethiazide.Approved
BenmoxinTramadol may increase the neuroexcitatory activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Tramadol is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Tramadol.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Tramadol.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Tramadol is combined with Benzyl alcohol.Approved
BetaxololThe therapeutic efficacy of Tramadol can be decreased when used in combination with Betaxolol.Approved
BexaroteneThe serum concentration of Tramadol can be decreased when it is combined with Bexarotene.Approved, Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Tramadol is combined with Bifeprunox.Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Tramadol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Tramadol.Investigational
BoceprevirThe serum concentration of Tramadol can be increased when it is combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Tramadol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Tramadol can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Tramadol is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved
BromazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Bromazepam.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Tramadol is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Tramadol is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Tramadol is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Tramadol is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Bupivacaine.Approved, Investigational
BuprenorphineTramadol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe therapeutic efficacy of Tramadol can be decreased when used in combination with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Tramadol is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Butabarbital.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Tramadol is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Tramadol is combined with Butethal.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Tramadol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cabergoline.Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Tramadol is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Canrenone.Investigational
CarbamazepineTramadol may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Tramadol is combined with Carfentanil.Illicit, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Tramadol is combined with Carisoprodol.Approved
CaroxazoneTramadol may increase the neuroexcitatory activities of Caroxazone.Withdrawn
CelecoxibThe therapeutic efficacy of Tramadol can be decreased when used in combination with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Tramadol can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Tramadol is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Chloroprocaine.Approved
ChloroquineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Tramadol.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Tramadol.Illicit, Withdrawn
ChlorpromazineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorzoxazone.Approved
CholecalciferolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cholecalciferol.Approved, Nutraceutical
CicletanineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cicletanine.Investigational
CimetidineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cimetidine.Approved
CinacalcetThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cinchocaine.Approved, Vet Approved
CitalopramCitalopram may increase the neuroexcitatory activities of Tramadol.Approved
ClarithromycinThe serum concentration of Tramadol can be increased when it is combined with Clarithromycin.Approved
ClemastineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Tramadol is combined with Clidinium.Approved
ClobazamThe therapeutic efficacy of Tramadol can be decreased when used in combination with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Tramadol is combined with clomethiazole.Investigational
ClomipramineClomipramine may increase the neuroexcitatory activities of Tramadol.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Clonidine.Approved
ClopidogrelThe metabolism of Tramadol can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Tramadol is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe therapeutic efficacy of Tramadol can be decreased when used in combination with Clotrimazole.Approved, Vet Approved
ClozapineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Clozapine.Approved
CobicistatThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cobicistat.Approved
CocaineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Tramadol is combined with Codeine.Approved, Illicit
ConivaptanThe serum concentration of Tramadol can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Tramadol can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the neuroexcitatory activities of Tramadol.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Tramadol.Approved
CyclosporineThe metabolism of Tramadol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Tramadol can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Tramadol is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Tramadol is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Tramadol.Investigational
DarifenacinThe therapeutic efficacy of Tramadol can be decreased when used in combination with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Tramadol can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Tramadol can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Tramadol can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Tramadol is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Tramadol is combined with Desflurane.Approved
DesipramineDesipramine may increase the neuroexcitatory activities of Tramadol.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Tramadol is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Tramadol is combined with Desmopressin.Approved
DesvenlafaxineDesvenlafaxine may increase the neuroexcitatory activities of Tramadol.Approved
DetomidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Tramadol can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Tramadol.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Tramadol.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Tramadol is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Tramadol is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Tramadol is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Diazepam.Approved, Illicit, Vet Approved
DicoumarolTramadol may increase the anticoagulant activities of Dicoumarol.Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tramadol.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Tramadol.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Tramadol is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Tramadol can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Tramadol is combined with Dimenhydrinate.Approved
DiphenhydramineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Tramadol is combined with Diphenoxylate.Approved, Illicit
DolasetronDolasetron may decrease the analgesic activities of Tramadol.Approved
DoramectinThe risk or severity of adverse effects can be increased when Tramadol is combined with Doramectin.Vet Approved
DosulepinDosulepin may increase the neuroexcitatory activities of Tramadol.Approved
DoxepinDoxepin may increase the neuroexcitatory activities of Tramadol.Approved
DoxorubicinThe metabolism of Tramadol can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Tramadol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Tramadol is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Illicit
DronedaroneThe therapeutic efficacy of Tramadol can be decreased when used in combination with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Tramadol is combined with Drotebanol.Experimental, Illicit
DuloxetineDuloxetine may increase the neuroexcitatory activities of Tramadol.Approved
DyclonineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Tramadol is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Tramadol can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Tramadol is combined with Efonidipine.Approved
EletriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Eletriptan.Approved, Investigational
EliglustatThe therapeutic efficacy of Tramadol can be decreased when used in combination with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Tramadol is combined with Pregnanolone.Investigational
EluxadolineTramadol may increase the constipating activities of Eluxadoline.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Tramadol is combined with Enflurane.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Tramadol is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Tramadol can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Eplerenone.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Tramadol is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ergotamine.Approved
ErythromycinThe metabolism of Tramadol can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramEscitalopram may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Tramadol can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineEsmirtazapine may increase the neuroexcitatory activities of Tramadol.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Tramadol is combined with Eszopiclone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Tramadol is combined with Etacrynic acid.Approved
EthanolTramadol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tramadol.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Tramadol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateTramadol may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Tramadol is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Tramadol is combined with Etomidate.Approved
EtoperidoneEtoperidone may increase the neuroexcitatory activities of Tramadol.Approved
EtorphineThe risk or severity of adverse effects can be increased when Tramadol is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Tramadol can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Tramadol is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Tramadol is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tramadol.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Tramadol is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Tramadol is combined with Flibanserin.Approved
FluconazoleThe metabolism of Tramadol can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Fludiazepam.Approved, Illicit
FluindioneTramadol may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Tramadol is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Flunitrazepam.Approved, Illicit
FluoxetineFluoxetine may increase the neuroexcitatory activities of Tramadol.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Tramadol is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Tramadol is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Tramadol is combined with Fluticasone Propionate.Approved
FluvoxamineFluvoxamine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
FosamprenavirThe metabolism of Tramadol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Tramadol can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Tramadol can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Frovatriptan.Approved, Investigational
FurazolidoneTramadol may increase the neuroexcitatory activities of Furazolidone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Tramadol is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Tramadol can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Tramadol is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Tramadol is combined with gabapentin enacarbil.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Tramadol.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Tramadol is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Tramadol is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Tramadol is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Tramadol.Approved, Investigational, Vet Approved
GranisetronGranisetron may decrease the analgesic activities of Tramadol.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Tramadol is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Tramadol is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Tramadol is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Tramadol.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Tramadol.Approved
HydracarbazineTramadol may increase the neuroexcitatory activities of Hydracarbazine.Experimental
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneTramadol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine hydrobromide may increase the analgesic activities of Tramadol.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Tramadol.Approved
IdelalisibThe serum concentration of Tramadol can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Iloperidone.Approved
ImatinibThe metabolism of Tramadol can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the neuroexcitatory activities of Tramadol.Approved
IndalpineIndalpine may increase the neuroexcitatory activities of Tramadol.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Tramadol is combined with Indapamide.Approved
IndinavirThe therapeutic efficacy of Tramadol can be decreased when used in combination with Indinavir.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tramadol.Approved
IproclozideTramadol may increase the neuroexcitatory activities of Iproclozide.Withdrawn
IproniazidTramadol may increase the neuroexcitatory activities of Iproniazid.Withdrawn
IsavuconazoniumThe metabolism of Tramadol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidTramadol may increase the neuroexcitatory activities of Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Tramadol is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe therapeutic efficacy of Tramadol can be decreased when used in combination with Isoniazid.Approved
IsosorbideThe risk or severity of adverse effects can be increased when Tramadol is combined with Isosorbide.Approved
IsradipineThe metabolism of Tramadol can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Tramadol can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Tramadol can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Ketobemidone.Approved
KetoconazoleThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Tramadol is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Tramadol is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Tramadol is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Tramadol is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Tramadol is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Tramadol is combined with Levomethadyl Acetate.Approved
LevomilnacipranLevomilnacipran may increase the neuroexcitatory activities of Tramadol.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Tramadol is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Tramadol is combined with Linezolid.Approved, Investigational
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Tramadol.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Tramadol is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Tramadol is combined with Lofentanil.Illicit
LopinavirThe serum concentration of Tramadol can be increased when it is combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Tramadol is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tramadol.Approved
LorcaserinThe therapeutic efficacy of Tramadol can be decreased when used in combination with Lorcaserin.Approved
LovastatinThe metabolism of Tramadol can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Tramadol is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Tramadol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Tramadol can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Tramadol is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Tramadol is combined with Maprotiline.Approved
MebanazineTramadol may increase the neuroexcitatory activities of Mebanazine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tramadol.Approved
MeclizineThe risk or severity of adverse effects can be increased when Tramadol is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Tramadol is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Tramadol.Investigational
MephentermineMephentermine may increase the analgesic activities of Tramadol.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Tramadol is combined with Meprobamate.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Tramadol is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Tramadol is combined with Metaxalone.Approved
MethadoneThe therapeutic efficacy of Tramadol can be decreased when used in combination with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Tramadol is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Tramadol.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Tramadol.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Tramadol is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Tramadol is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Methohexital.Approved
MethotrimeprazineTramadol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Tramadol is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Tramadol is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Tramadol is combined with ECGONINE METHYL ESTER.Experimental
Methylene blueTramadol may increase the neuroexcitatory activities of Methylene blue.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Methylphenobarbital.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Tramadol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Tramadol is combined with Metoclopramide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Tramadol.Approved, Investigational
MetyrosineTramadol may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Tramadol can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the neuroexcitatory activities of Tramadol.Approved
MinaprineTramadol may increase the neuroexcitatory activities of Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Investigational
MirabegronThe therapeutic efficacy of Tramadol can be decreased when used in combination with Mirabegron.Approved
MirtazapineMirtazapine may increase the neuroexcitatory activities of Tramadol.Approved
MitotaneThe serum concentration of Tramadol can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may increase the analgesic activities of Tramadol.Experimental, Illicit
MoclobemideTramadol may increase the neuroexcitatory activities of Moclobemide.Approved
ModafinilThe serum concentration of Tramadol can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Tramadol.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Tramadol is combined with Morphine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Investigational
NafcillinThe serum concentration of Tramadol can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may decrease the analgesic activities of Tramadol.Approved
NaltrexoneThe therapeutic efficacy of Tramadol can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Naratriptan.Approved, Investigational
NefazodoneNefazodone may increase the neuroexcitatory activities of Tramadol.Approved, Withdrawn
NelfinavirThe serum concentration of Tramadol can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Tramadol can be increased when it is combined with Netupitant.Approved
NevirapineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Nevirapine.Approved
NialamideTramadol may increase the neuroexcitatory activities of Nialamide.Withdrawn
NicardipineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Nicardipine.Approved
NilotinibThe therapeutic efficacy of Tramadol can be decreased when used in combination with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Tramadol is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Tramadol is combined with 1,1,1,2 Tetrafluoroethane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the neuroexcitatory activities of Tramadol.Approved
OctamoxinTramadol may increase the neuroexcitatory activities of Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Tramadol is combined with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Tramadol can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Tramadol is combined with Olopatadine.Approved
OndansetronOndansetron may decrease the analgesic activities of Tramadol.Approved
OpipramolOpipramol may increase the neuroexcitatory activities of Tramadol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Tramadol is combined with Opium.Approved, Illicit
OrphenadrineTramadol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Tramadol is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Tramadol can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Tramadol.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Tramadol.Approved
PalbociclibThe serum concentration of Tramadol can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Paliperidone.Approved
PalonosetronPalonosetron may decrease the analgesic activities of Tramadol.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Tramadol.Approved
PanobinostatThe serum concentration of Tramadol can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeTramadol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineTramadol may increase the neuroexcitatory activities of Pargyline.Approved
ParoxetineParoxetine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Tramadol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tramadol.Approved
PentazocinePentazocine may decrease the analgesic activities of Tramadol.Approved, Vet Approved
PentobarbitalThe metabolism of Tramadol can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Tramadol.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved
PerazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Tramadol is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Pethidine.Approved
PhenelzineTramadol may increase the neuroexcitatory activities of Phenelzine.Approved
PhenindioneTramadol may increase the anticoagulant activities of Phenindione.Approved
PheniprazineTramadol may increase the neuroexcitatory activities of Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Tramadol can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Tramadol is combined with Phenoxyethanol.Approved
PhenoxypropazineTramadol may increase the neuroexcitatory activities of Phenoxypropazine.Withdrawn
PhenprocoumonTramadol may increase the anticoagulant activities of Phenprocoumon.Approved
PhenterminePhentermine may increase the analgesic activities of Tramadol.Approved, Illicit
PhenytoinThe metabolism of Tramadol can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Tramadol is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Tramadol.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Tramadol.Approved
PiretanideThe risk or severity of adverse effects can be increased when Tramadol is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Tramadol is combined with Piritramide.Investigational
PirlindoleTramadol may increase the neuroexcitatory activities of Pirlindole.Approved
PivhydrazineTramadol may increase the neuroexcitatory activities of Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Tramadol is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Tramadol is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Tramadol can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Tramadol is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Tramadol is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleTramadol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Tramadol is combined with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Prilocaine.Approved
PrimidoneThe metabolism of Tramadol can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Prochlorperazine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Tramadol.Approved
PromazineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Promethazine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Tramadol.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Propericiazine.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Tramadol.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Tramadol.Investigational
PropofolThe risk or severity of adverse effects can be increased when Tramadol is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Propoxycaine.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Tramadol is combined with Prothipendyl.Investigational
ProtriptylineProtriptyline may increase the neuroexcitatory activities of Tramadol.Approved
PSD502The risk or severity of adverse effects can be increased when Tramadol is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Tramadol.Approved
QuazepamThe serum concentration of Tramadol can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Tramadol is combined with Quetiapine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Quinethazone.Approved
QuinidineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Quinidine.Approved
QuinineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Tramadol is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Tramadol is combined with Ramelteon.Approved, Investigational
RamosetronTramadol may increase the constipating activities of Ramosetron.Approved
RanolazineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ranolazine.Approved, Investigational
RasagilineTramadol may increase the neuroexcitatory activities of Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Tramadol is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Tramadol is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Tramadol is combined with Reserpine.Approved
RifabutinThe metabolism of Tramadol can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Tramadol can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Tramadol can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Tramadol is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Tramadol.Investigational
RitonavirThe serum concentration of Tramadol can be increased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Rizatriptan.Approved
RolapitantThe therapeutic efficacy of Tramadol can be decreased when used in combination with Rolapitant.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Tramadol is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Romifidine.Vet Approved
RopiniroleThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ropivacaine.Approved
RotigotineTramadol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tramadol.Approved
SafrazineTramadol may increase the neuroexcitatory activities of Safrazine.Withdrawn
SaquinavirThe serum concentration of Tramadol can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Tramadol.Approved, Vet Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Secobarbital.Approved, Vet Approved
SelegilineTramadol may increase the neuroexcitatory activities of Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Tramadol is combined with Uc1010.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Tramadol is combined with Sertindole.Approved, Withdrawn
SertralineSertraline may increase the neuroexcitatory activities of Tramadol.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Tramadol is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Tramadol can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Tramadol can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Tramadol can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Tramadol.Approved
SorafenibThe metabolism of Tramadol can be decreased when combined with Sorafenib.Approved, Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Tramadol can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StiripentolThe serum concentration of Tramadol can be increased when it is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Tramadol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Tramadol is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Tramadol can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Tramadol is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Sumatriptan.Approved, Investigational
SuvorexantTramadol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tramadol is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tramadol is combined with Tasimelteon.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Tramadol.Approved
TelaprevirThe serum concentration of Tramadol can be increased when it is combined with Telaprevir.Withdrawn
TelithromycinThe serum concentration of Tramadol can be increased when it is combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Temazepam.Approved
TerbinafineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tramadol is combined with Tetrodotoxin.Investigational
ThalidomideTramadol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Tramadol is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Tramadol is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Tramadol.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Tramadol is combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Tramadol.Withdrawn
ThiotepaThe metabolism of Tramadol can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Tramadol is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tramadol is combined with Tiagabine.Approved
TianeptineTianeptine may increase the neuroexcitatory activities of Tramadol.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tramadol is combined with Tiapride.Approved, Investigational
TiclopidineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Tramadol is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Tiletamine.Vet Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Tramadol.Approved
TipranavirThe therapeutic efficacy of Tramadol can be decreased when used in combination with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Tramadol can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tramadol is combined with Tolcapone.Approved, Withdrawn
ToloxatoneTramadol may increase the neuroexcitatory activities of Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Tramadol.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Tramadol is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Tramadol is combined with Torasemide.Approved
Trans-2-PhenylcyclopropylamineTramadol may increase the neuroexcitatory activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineTramadol may increase the neuroexcitatory activities of Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Trazodone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Tramadol is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Triazolam.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Tramadol.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Tramadol.Approved
TrimipramineTrimipramine may increase the neuroexcitatory activities of Tramadol.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Triprolidine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Tramadol.Approved
TropisetronTropisetron may decrease the analgesic activities of Tramadol.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Tramadol.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Tramadol.Approved
UlaritideThe risk or severity of adverse effects can be increased when Tramadol is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Tramadol.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Tramadol is combined with Valproic Acid.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Tramadol.Approved
VenlafaxineVenlafaxine may increase the neuroexcitatory activities of Tramadol.Approved
VerapamilThe metabolism of Tramadol can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Tramadol is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Vilazodone.Approved
VoriconazoleThe serum concentration of Tramadol can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Tramadol is combined with Vortioxetine.Approved
WarfarinTramadol may increase the anticoagulant activities of Warfarin.Approved
XylazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Tramadol is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Tramadol is combined with Ziconotide.Approved
ZimelidineZimelidine may increase the neuroexcitatory activities of Tramadol.Withdrawn
ZiprasidoneThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Zolmitriptan.Approved, Investigational
ZolpidemTramadol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Tramadol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Tramadol is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Tramadol is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Tramadol is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Oral administration of tramadol hydrochloride with food does not significantly affect its rate or extent of absorption, therefore, tramadol hydrochloride can be administered without regard to food.

References

Synthesis Reference

Wolfgang Reimann, "Combination preparation containing tramadol and a calcium channel antagonist." U.S. Patent US5929122, issued March, 1993.

US5929122
General References
  1. Dayer P, Desmeules J, Collart L: [Pharmacology of tramadol]. Drugs. 1997;53 Suppl 2:18-24. [PubMed:9190321 ]
  2. Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, Donofrio P, Cornblath D, Sachdeo R, Siu CO, Kamin M: Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998 Jun;50(6):1842-6. [PubMed:9633738 ]
  3. Harati Y, Gooch C, Swenson M, Edelman SV, Greene D, Raskin P, Donofrio P, Cornblath D, Olson WH, Kamin M: Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications. 2000 Mar-Apr;14(2):65-70. [PubMed:10959067 ]
  4. Gobel H, Stadler T: [Treatment of post-herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine]. Drugs. 1997;53 Suppl 2:34-9. [PubMed:9190323 ]
  5. Boureau F, Legallicier P, Kabir-Ahmadi M: Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain. 2003 Jul;104(1-2):323-31. [PubMed:12855342 ]
External Links
Human Metabolome Database
HMDB14339
KEGG Drug
D08623
KEGG Compound
C07153
PubChem Compound
33741
PubChem Substance
46506256
ChemSpider
31105
BindingDB
50176259
ChEBI
75725
ChEMBL
CHEMBL1066
Therapeutic Targets Database
DAP000140
PharmGKB
PA451735
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Tramadol
ATC Codes
N02AX52 — Tramadol, combinationsN02AX02 — Tramadol
AHFS Codes
  • 28:08.08
PDB Entries
Not Available
FDA label
Download (408 KB)
MSDS
Download (74.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableOsteoarthritis Thumbs1
1CompletedNot AvailablePain1
1CompletedNot AvailableTo Determine Bioequivalence Under Fasting Conditions1
1CompletedNot AvailableTo Determine Bioequivalence Under Fed Conditions1
1CompletedBasic ScienceAging / Pain1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedDiagnosticSynovitis of osteoarthritis1
1CompletedTreatmentPain4
1, 2CompletedBasic ScienceOpioid Induced Motor Disturbances1
1, 2CompletedTreatmentOpioid Abuse / Opioid Addiction / Stimulant Abuse / Stimulant Addiction1
1, 2CompletedTreatmentOpioid Addiction / Opioid Dependence / Opioid Related Disorders1
1, 2CompletedTreatmentOpioid-Related Disorders1
1, 2CompletedTreatmentPain Management / Pulpitis dental1
1, 2Unknown StatusTreatmentChoroidal Melanoma / Eye Neoplasms / Melanoma1
2CompletedSupportive CarePain2
2CompletedTreatmentFibromyalgia / Growth Hormone Deficiency (GHD)1
2CompletedTreatmentGeriatric Hip Fracture Pain Management1
2CompletedTreatmentOpioid-Related Disorders1
2CompletedTreatmentPain1
2Not Yet RecruitingPreventionPost Anaesthetic Shivering1
2Not Yet RecruitingTreatmentTramadol for Labor Analgesia1
2RecruitingPreventionPain, Neuropathic1
2RecruitingSupportive CareCancer, Breast1
2RecruitingTreatmentPain, Acute1
2Unknown StatusTreatmentNausea / Pain / Pruritus / Vertigo1
2, 3CompletedTreatmentSubstance Withdrawal Syndrome1
3CompletedTreatmentAcute Low Back Pain1
3CompletedTreatmentAnaesthesia therapy1
3CompletedTreatmentAnalgesia / Neonatal Infections / Pain1
3CompletedTreatmentDiabetic Neuropathies1
3CompletedTreatmentLow Back Pain (LBP)1
3CompletedTreatmentPain During Labour1
3CompletedTreatmentPain, Chronic1
3CompletedTreatmentPain / Postoperative pain1
3CompletedTreatmentPostoperative pain1
3Not Yet RecruitingPreventionPain, Procedure1
3RecruitingPreventionHysteroscopy2
3RecruitingPreventionHysteroscopy / Pain1
3RecruitingPreventionPain1
3RecruitingPreventionPain, Post Procedural / Procedural Pain1
3RecruitingTreatmentAbdominal Pain (AP)1
3RecruitingTreatmentFibromyalgia1
3RecruitingTreatmentAdjunct to general anesthesia therapy / Indwelling Urinary Catheter / Male Patients1
3RecruitingTreatmentPain, Acute2
3RecruitingTreatmentPain, Chronic1
3TerminatedNot AvailablePremature Ejaculation1
3Unknown StatusTreatmentHip Arthroplasty / Knee Replacement Surgery / Spinal Anaesthesia1
4CompletedNot AvailablePain, Chronic1
4CompletedNot AvailableRheumatic Diseases1
4CompletedHealth Services ResearchAnkylosing Spondylitis (AS)1
4CompletedPreventionChronic Diseases1
4CompletedPreventionPostoperative pain1
4CompletedSupportive CarePostoperative pain / Prophylaxis against postoperative nausea and vomiting1
4CompletedTreatmentArthroplasty1
4CompletedTreatmentBack Pain1
4CompletedTreatmentCancers1
4CompletedTreatmentChildren / Inguinal Hernias1
4CompletedTreatmentChildren / Postoperative pain / Recovery of Function1
4CompletedTreatmentDiabetic Neuropathies1
4CompletedTreatmentFibromyalgia / Pain1
4CompletedTreatmentFracture Bone / Pain1
4CompletedTreatmentGall Stone Disease1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHeart Surgery Via Sternotomy / Post-operative Analgesia1
4CompletedTreatmentHernia1
4CompletedTreatmentHysterectomy / Postoperative pain1
4CompletedTreatmentInadequate or Impaired Respiratory Function / Pain1
4CompletedTreatmentPain2
4CompletedTreatmentPain, Acute1
4CompletedTreatmentPain / Tonsillitis1
4CompletedTreatmentPain / Synovitis of osteoarthritis1
4CompletedTreatmentOr Peripheral Nerve Injury (PNI) / Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN)1
4CompletedTreatmentPostoperative pain4
4CompletedTreatmentPostoperative pain / Spinal Stenosis1
4CompletedTreatmentRotator Cuff Syndrome1
4CompletedTreatmentSynovitis of osteoarthritis1
4Not Yet RecruitingHealth Services ResearchIUD Insertion Complication1
4Not Yet RecruitingPreventionPain1
4Not Yet RecruitingTreatmentChild, Only / Postoperative pain / Sleep Disorder; Breathing-Related1
4RecruitingNot AvailablePolyps, Nasal1
4RecruitingPreventionNeoplasms, Brain1
4RecruitingSupportive CareColon Diverticulosis / Colonic Neoplasms / Constipation Drug Induced / Diverticulitis, Colonic / Ileus / Ileus paralytic / Ileus; Mechanical / Malignant Neoplasm of Colon / Occasional Constipation / Postoperative pain / Rectum Cancer / Rectum Neoplasm1
4RecruitingTreatmentPain1
4TerminatedTreatmentAnkylosing Spondylitis (AS) / Pain1
4TerminatedTreatmentPain1
4Unknown StatusTreatmentDepressive State / Pain1
4Unknown StatusTreatmentLaparoscopic Nissen Fundoplication1
4Unknown StatusTreatmentPain1
4Unknown StatusTreatmentPost Operative Pain1
4Unknown StatusTreatmentPost-Traumatic Stress Disorder (PTSD)1
4WithdrawnTreatmentDiabetic Polyneuropathy / Postherpetic Neuralgia1
Not AvailableActive Not RecruitingNot AvailablePostoperative pain / Pregnancy1
Not AvailableActive Not RecruitingBasic ScienceHealthy Volunteers1
Not AvailableActive Not RecruitingTreatmentSpinal Stenosis of Lumbar Region1
Not AvailableCompletedNot AvailablePost-operative Patients Treated by Tramadol1
Not AvailableCompletedOtherTramadol - Anesthetics- Child - Circumcision1
Not AvailableCompletedSupportive CarePain, Acute1
Not AvailableCompletedSupportive CarePostoperative pain1
Not AvailableCompletedTreatmentCaudal epidural block therapy / Pain Management / Ultrasound1
Not AvailableCompletedTreatmentPeriapical Abscess1
Not AvailableCompletedTreatmentPost Cesarean Pain Management1
Not AvailableCompletedTreatmentPostoperative Sedation, Abdominal Surgery1
Not AvailableCompletedTreatmentPostoperative pain2
Not AvailableCompletedTreatmentPregnancy Termination1
Not AvailableCompletedTreatmentProphylaxis against postoperative nausea and vomiting1
Not AvailableEnrolling by InvitationSupportive CareCancer, Breast / Radical Mastectomy Surgery1
Not AvailableNot Yet RecruitingTreatmentCatheter Site Discomfort1
Not AvailableRecruitingDiagnosticLumbar Disc Disease1
Not AvailableRecruitingTreatmentGeneral Surgery / Pain / Rib Fractures / Traumas1
Not AvailableRecruitingTreatmentLow Back Pain (LBP)1
Not AvailableRecruitingTreatmentPostoperative Sedation,Gastrectomy, Enhanced Recovery After Surgery1
Not AvailableRecruitingTreatmentSecond Degree Burns1
Not AvailableTerminatedScreeningCytochrome P450 Phenotype and Genotype Metrics1
Not AvailableUnknown StatusTreatmentFlail Chest / General Surgery / Rib Fractures / Traumas1
Not AvailableUnknown StatusTreatmentPain Relief1
Not AvailableUnknown StatusTreatmentPeritonsillar Abscess1
Not AvailableUnknown StatusTreatmentPostoperative pain1
Not AvailableWithdrawnTreatmentPostoperative pain1

Pharmacoeconomics

Manufacturers
  • Cipher pharmaceuticals inc
  • Purdue pharma products lp
  • Par pharmaceutical
  • Biovail laboratories international srl
  • Victory pharma inc
  • Actavis elizabeth llc
  • Alphapharm party ltd
  • Amneal pharmaceuticals llc
  • Apotex inc
  • Asta medica inc
  • Caraco pharmaceutical laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mallinckrodt inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Northstar healthcare holdings ltd
  • Pliva inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories
  • Ortho mcneil janssen pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseOral100 mg/1
Capsule, extended releaseOral200 mg/1
Capsule, extended releaseOral300 mg/1
Capsule, extended releaseOral100 mg
Capsule, extended releaseOral200 mg
Capsule, extended releaseOral300 mg
Tablet, extended releaseOral100 mg/1
Tablet, extended releaseOral200 mg/1
Tablet, extended releaseOral300 mg/1
Kit
KitOral
CreamTopical
CapsuleOral150 mg/1
Capsule, coated, extended releaseOral150 mg/1
Capsule, extended releaseOral150 mg/1
TabletOral50 mg/50mg
TabletOral50 mg/1
Tablet, coatedOral50 mg/1
Tablet, film coatedOral50 mg/1
Tablet, coatedOral
Tablet, film coatedOral
CapsuleOral100 mg/1
CapsuleOral200 mg/1
CapsuleOral300 mg/1
Tablet, film coated, extended releaseOral100 mg/1
Tablet, film coated, extended releaseOral200 mg/1
Tablet, film coated, extended releaseOral300 mg/1
Kit
Tablet, extended releaseOral100 mg
TabletOral
TabletOral50 mg
Tablet, coatedOral50 mg/201
TabletOral100 mg/1
Tablet, extended releaseOral150 mg
Tablet, extended releaseOral200 mg
Tablet, extended releaseOral300 mg
Tablet, extended releaseOral400 mg
Tablet, extended releaseOral75 mg
Prices
Unit descriptionCostUnit
Tramadol hcl powder29.08USD g
Ultram ER 300 mg 24 Hour tablet10.66USD tablet
Ultram er 300 mg tablet10.25USD tablet
Ultram ER 200 mg 24 Hour tablet7.64USD tablet
Ultram er 200 mg tablet7.35USD tablet
TraMADol HCl 200 mg 24 Hour tablet6.25USD tablet
Ultram ER 100 mg 24 Hour tablet4.62USD tablet
Ultram er 100 mg tablet4.44USD tablet
TraMADol HCl 100 mg 24 Hour tablet3.78USD tablet
Ultram 50 mg tablet1.99USD tablet
Tramadol-Acetaminophen 37.5-325 mg tablet1.07USD tablet
Tramadol hcl 50 mg tablet0.7USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5464632 No1993-03-222013-03-22Us
CA2476201 No2009-09-012023-02-21Canada
CA2123160 No2003-04-292014-05-09Canada
US6339105 Yes2000-04-122020-04-12Us
US6106861 No1997-12-052017-12-05Us
US6607748 No2000-06-292020-06-29Us
US7988998 No2003-10-272023-10-27Us
US7858118 No2002-04-112022-04-11Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)180-181 °CNot Available
water solubilitySoluble Not Available
logP2.4FDA label
pKa9.41FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.75 mg/mLALOGPS
logP2.71ALOGPS
logP2.45ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)13.8ChemAxon
pKa (Strongest Basic)9.23ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area32.7 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity78.27 m3·mol-1ChemAxon
Polarizability30.45 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9924
Blood Brain Barrier+0.9382
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.6283
P-glycoprotein inhibitor IInhibitor0.7807
P-glycoprotein inhibitor IIInhibitor0.9589
Renal organic cation transporterNon-inhibitor0.6398
CYP450 2C9 substrateNon-substrate0.7678
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7726
CYP450 1A2 substrateNon-inhibitor0.7136
CYP450 2C9 inhibitorNon-inhibitor0.704
CYP450 2D6 inhibitorInhibitor0.6566
CYP450 2C19 inhibitorNon-inhibitor0.6841
CYP450 3A4 inhibitorNon-inhibitor0.6256
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7832
Ames testNon AMES toxic0.7899
CarcinogenicityNon-carcinogens0.6663
BiodegradationNot ready biodegradable0.9975
Rat acute toxicity3.0316 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6136
hERG inhibition (predictor II)Inhibitor0.7098
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0090000000-7850be0ba78033f1f677
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0090000000-62a3c5cb6717bff20e2c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-05fs-0930000000-b8297a71c45e9630f6c0
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-05fr-0900000000-f650c49b70db20869d0f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0adl-0900000000-b17dfc32e2eb57efaf42
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0090000000-c35bec467cfec28511fb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-1090000000-9ca08dcdc5a2027bcb03
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9030000000-469467d2583e7202d89f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9000000000-89f055b497c88cdc5e79
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9000000000-1922068301c6d3b4f457
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9000000000-1922068301c6d3b4f457
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9000000000-5a9396f20ce15b9c08ba
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-1090000000-e040861e9fa18a8f44a5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9030000000-fa1522b6a491e6da41c9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9000000000-8ab0ebc3ceff7c5e5ce5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9000000000-7645dc9b29d8b2867495
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9000000000-70cad0a31ff2d57bab81
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-9000000000-bf1b2c15c6511355c9e1
Predicted LC-MS/MS Spectrum - 10V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 10V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, NegativePredicted LC-MS/MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0a4i-9010000000-ffea37e400f0860f2e7f

Taxonomy

Description
This compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Anisoles
Direct Parent
Anisoles
Alternative Parents
Phenoxy compounds / Methoxybenzenes / Cyclohexanols / Aralkylamines / Alkyl aryl ethers / Tertiary alcohols / Trialkylamines / Cyclic alcohols and derivatives / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenoxy compound / Anisole / Methoxybenzene / Alkyl aryl ether / Cyclohexanol / Aralkylamine / Monocyclic benzene moiety / Tertiary alcohol / Cyclic alcohol / Tertiary aliphatic amine
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol (CHEBI:75725 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Gillen C, Haurand M, Kobelt DJ, Wnendt S: Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol. 2000 Aug;362(2):116-21. [PubMed:10961373 ]
  2. Potschka H, Friderichs E, Loscher W: Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its M1 metabolite in the rat kindling model of epilepsy. Br J Pharmacol. 2000 Sep;131(2):203-12. [PubMed:10991912 ]
  3. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL: Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther. 1992 Jan;260(1):275-85. [PubMed:1309873 ]
  4. Grond S, Sablotzki A: Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923. [PubMed:15509185 ]
  5. Ide S, Minami M, Ishihara K, Uhl GR, Sora I, Ikeda K: Mu opioid receptor-dependent and independent components in effects of tramadol. Neuropharmacology. 2006 Sep;51(3):651-8. Epub 2006 Jun 21. [PubMed:16793069 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Minami K, Uezono Y, Ueta Y: Pharmacological aspects of the effects of tramadol on G-protein coupled receptors. J Pharmacol Sci. 2007 Mar;103(3):253-60. [PubMed:17380034 ]
  8. Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung. 1996 Nov;46(11):1029-36. [PubMed:8955860 ]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Sagata K, Minami K, Yanagihara N, Shiraishi M, Toyohira Y, Ueno S, Shigematsu A: Tramadol inhibits norepinephrine transporter function at desipramine-binding sites in cultured bovine adrenal medullary cells. Anesth Analg. 2002 Apr;94(4):901-6, table of contents. [PubMed:11916794 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Berrocoso E, Mico JA: Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression. Int J Neuropsychopharmacol. 2009 Sep;12(8):1033-44. doi: 10.1017/S1461145709000236. Epub 2009 Apr 3. [PubMed:19341511 ]
  4. Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung. 1996 Nov;46(11):1029-36. [PubMed:8955860 ]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Barann M, Urban B, Stamer U, Dorner Z, Bonisch H, Bruss M: Effects of tramadol and O-demethyl-tramadol on human 5-HT reuptake carriers and human 5-HT3A receptors: a possible mechanism for tramadol-induced early emesis. Eur J Pharmacol. 2006 Feb 15;531(1-3):54-8. Epub 2006 Jan 19. [PubMed:16427041 ]
  2. Driessen B, Reimann W: Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro. Br J Pharmacol. 1992 Jan;105(1):147-51. [PubMed:1596676 ]
  3. Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung. 1996 Nov;46(11):1029-36. [PubMed:8955860 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Ogata J, Minami K, Uezono Y, Okamoto T, Shiraishi M, Shigematsu A, Ueta Y: The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents. [PubMed:15105221 ]
  2. Horishita T, Minami K, Uezono Y, Shiraishi M, Ogata J, Okamoto T, Shigematsu A: The tramadol metabolite, O-desmethyl tramadol, inhibits 5-hydroxytryptamine type 2C receptors expressed in Xenopus Oocytes. Pharmacology. 2006;77(2):93-9. Epub 2006 May 5. [PubMed:16679816 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Sun HL, Zheng JW, Wang K, Liu RK, Liang JH: Tramadol reduces the 5-HTP-induced head-twitch response in mice via the activation of mu and kappa opioid receptors. Life Sci. 2003 Jan 31;72(11):1221-30. [PubMed:12570923 ]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Wentland MP, Lou R, Lu Q, Bu Y, VanAlstine MA, Cohen DJ, Bidlack JM: Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. doi: 10.1016/j.bmcl.2008.10.134. Epub 2008 Nov 7. [PubMed:19027293 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein phosphatase 2a binding
Specific Function
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May ...
Gene Name
GRIN3A
Uniprot ID
Q8TCU5
Uniprot Name
Glutamate receptor ionotropic, NMDA 3A
Molecular Weight
125464.07 Da
References
  1. Hara K, Minami K, Sata T: The effects of tramadol and its metabolite on glycine, gamma-aminobutyric acidA, and N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Anesth Analg. 2005 May;100(5):1400-5, table of contents. [PubMed:15845694 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Not Available
Specific Function
Not Available
Gene Name
CHRNA7
Uniprot ID
Q693P7
Uniprot Name
Alpha-7 nicotinic cholinergic receptor subunit
Molecular Weight
2987.635 Da
References
  1. Shiraishi M, Minami K, Uezono Y, Yanagihara N, Shigematsu A, Shibuya I: Inhibitory effects of tramadol on nicotinic acetylcholine receptors in adrenal chromaffin cells and in Xenopus oocytes expressing alpha 7 receptors. Br J Pharmacol. 2002 May;136(2):207-16. [PubMed:12010769 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Shiraishi M, Minami K, Uezono Y, Yanagihara N, Shigematsu A: Inhibition by tramadol of muscarinic receptor-induced responses in cultured adrenal medullary cells and in Xenopus laevis oocytes expressing cloned M1 receptors. J Pharmacol Exp Ther. 2001 Oct;299(1):255-60. [PubMed:11561087 ]
  2. Shiga Y, Minami K, Shiraishi M, Uezono Y, Murasaki O, Kaibara M, Shigematsu A: The inhibitory effects of tramadol on muscarinic receptor-induced responses in Xenopus oocytes expressing cloned M(3) receptors. Anesth Analg. 2002 Nov;95(5):1269-73, table of contents. [PubMed:12401609 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:24